Back to Newsroom

Endocyte Announces Presentations at AACR Annual Meeting 2014

Data for Endocyte’s Folate Receptor (FR)-Targeting Folate-Tubulysin Conjugate, EC1456, and Prostate-Specific Membrane Antigen (PSMA)-Targeted Tubulysin, SMDC, EC1169, to be Presented

WEST LAFAYETTE, Ind., April 4, 2014 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that three posters will be presented by Endocyte scientists at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) to be held in San Diego, April 5-9, 2014.

Click here to read more